1. Roche said it’s acquiring cancer biotech Ignyta for $1.7 billion to expand its oncology portfolio. The San Diego-based biotech develops therapies for cancers with rare mutations. Its experimental drug entrectinib targets ROS1 fusion genes in NSCLC cases and NTRK fusions across a range of tumors. (Endpoints News)
2. Valeant received FDA-approval to sell eye care subsidiary Bausch & Lomb’s Lumify eye drop over-the-counter. (Reuters)
3. Kmart and parent company Sears Holding Corporation will pay $59 million to settle allegations that it engaged in prescription drug fraud, which included offering discounts on generic drugs to cash-paying customers without notifying the federal government. (CNN Money)
4. Oscar Health, Centene, Cigna and Blue Cross and Blue Shield plans stand to benefit from the Affordable Care Act in 2018, thanks to less competition and substantial price increases. The plans all said they will continue providing coverage to individuals under the ACA. (Forbes)
5. Israeli pharmacy giant Super-Pharm is reportedly discussing the acquisition of Teva Pharmaceutical Industries’ plant in Ashdod for up to $23 million. (Reuters)
